Selected research
Industry Research
CGT Drugs Industry Research Report 2026
Market perspective
The global CGT Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for CGT Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for CGT Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of CGT Drugs include Bluebird Bio, Celgene Corporation, Juno Therapeutics, Kite Pharma, Orchard Therapeutics, Spark Therapeutics, Amgen, Fosun Kite Biotechnology and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global CGT Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CGT Drugs Market by Company
Bluebird Bio
Celgene Corporation
Juno Therapeutics
Kite Pharma
Orchard Therapeutics
Spark Therapeutics
Amgen
Fosun Kite Biotechnology
GSK
Novartis
SiBiono
Sunway Biotech
Janssen Biotech
Sequoia
CGT Drugs Segment by Type
CAR-T Therapy
Viral Vector Therapy
Stem Cell Therapy
Oncolytic Virus Therapy
CGT Drugs Segment by Application
Tumor Disease
Eye Disease
Rare Disease
Others
CGT Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGT Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGT Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGT Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of CGT Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of CGT Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of CGT Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CAR-T Therapy
- Viral Vector Therapy
- Stem Cell Therapy
- Oncolytic Virus Therapy
Applications
- Tumor Disease
- Eye Disease
- Rare Disease
- Others
Companies covered
- Bluebird Bio
- Celgene Corporation
- Juno Therapeutics
- Kite Pharma
- Orchard Therapeutics
- Spark Therapeutics
- Amgen
- Fosun Kite Biotechnology
- GSK
- Novartis
- SiBiono
- Sunway Biotech
- Janssen Biotech
- Sequoia
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global CGT Drugs Market Size (2021-2032)
- 2.2.2 Global CGT Drugs Sales (2021-2032)
- 2.2.3 Global CGT Drugs Market Average Price (2021-2032)
- 2.3 CGT Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CAR-T Therapy
- 2.3.3 Viral Vector Therapy
- 2.3.4 Stem Cell Therapy
- 2.3.5 Oncolytic Virus Therapy
- 2.4 CGT Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tumor Disease
- 2.4.3 Eye Disease
- 2.4.4 Rare Disease
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global CGT Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global CGT Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global CGT Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global CGT Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global CGT Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of CGT Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of CGT Drugs, Product Type & Application
- 3.8 Global Manufacturers of CGT Drugs, Established Date
- 3.9 Global CGT Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bluebird Bio
- 4.1.1 Bluebird Bio Company Information
- 4.1.2 Bluebird Bio Business Overview
- 4.1.3 Bluebird Bio CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bluebird Bio CGT Drugs Product Portfolio
- 4.1.5 Bluebird Bio Recent Developments
- 4.2 Celgene Corporation
- 4.2.1 Celgene Corporation Company Information
- 4.2.2 Celgene Corporation Business Overview
- 4.2.3 Celgene Corporation CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Celgene Corporation CGT Drugs Product Portfolio
- 4.2.5 Celgene Corporation Recent Developments
- 4.3 Juno Therapeutics
- 4.3.1 Juno Therapeutics Company Information
- 4.3.2 Juno Therapeutics Business Overview
- 4.3.3 Juno Therapeutics CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Juno Therapeutics CGT Drugs Product Portfolio
- 4.3.5 Juno Therapeutics Recent Developments
- 4.4 Kite Pharma
- 4.4.1 Kite Pharma Company Information
- 4.4.2 Kite Pharma Business Overview
- 4.4.3 Kite Pharma CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kite Pharma CGT Drugs Product Portfolio
- 4.4.5 Kite Pharma Recent Developments
- 4.5 Orchard Therapeutics
- 4.5.1 Orchard Therapeutics Company Information
- 4.5.2 Orchard Therapeutics Business Overview
- 4.5.3 Orchard Therapeutics CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Orchard Therapeutics CGT Drugs Product Portfolio
- 4.5.5 Orchard Therapeutics Recent Developments
- 4.6 Spark Therapeutics
- 4.6.1 Spark Therapeutics Company Information
- 4.6.2 Spark Therapeutics Business Overview
- 4.6.3 Spark Therapeutics CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Spark Therapeutics CGT Drugs Product Portfolio
- 4.6.5 Spark Therapeutics Recent Developments
- 4.7 Amgen
- 4.7.1 Amgen Company Information
- 4.7.2 Amgen Business Overview
- 4.7.3 Amgen CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Amgen CGT Drugs Product Portfolio
- 4.7.5 Amgen Recent Developments
- 4.8 Fosun Kite Biotechnology
- 4.8.1 Fosun Kite Biotechnology Company Information
- 4.8.2 Fosun Kite Biotechnology Business Overview
- 4.8.3 Fosun Kite Biotechnology CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Fosun Kite Biotechnology CGT Drugs Product Portfolio
- 4.8.5 Fosun Kite Biotechnology Recent Developments
- 4.9 GSK
- 4.9.1 GSK Company Information
- 4.9.2 GSK Business Overview
- 4.9.3 GSK CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GSK CGT Drugs Product Portfolio
- 4.9.5 GSK Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis CGT Drugs Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 SiBiono
- 4.11.1 SiBiono Company Information
- 4.11.2 SiBiono Business Overview
- 4.11.3 SiBiono CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 SiBiono CGT Drugs Product Portfolio
- 4.11.5 SiBiono Recent Developments
- 4.12 Sunway Biotech
- 4.12.1 Sunway Biotech Company Information
- 4.12.2 Sunway Biotech Business Overview
- 4.12.3 Sunway Biotech CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sunway Biotech CGT Drugs Product Portfolio
- 4.12.5 Sunway Biotech Recent Developments
- 4.13 Janssen Biotech
- 4.13.1 Janssen Biotech Company Information
- 4.13.2 Janssen Biotech Business Overview
- 4.13.3 Janssen Biotech CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Janssen Biotech CGT Drugs Product Portfolio
- 4.13.5 Janssen Biotech Recent Developments
- 4.14 Sequoia
- 4.14.1 Sequoia Company Information
- 4.14.2 Sequoia Business Overview
- 4.14.3 Sequoia CGT Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Sequoia CGT Drugs Product Portfolio
- 4.14.5 Sequoia Recent Developments
5 Global CGT Drugs Market Scenario by Region
- 5.1 Global CGT Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global CGT Drugs Sales by Region: 2021-2032
- 5.2.1 Global CGT Drugs Sales by Region: 2021-2026
- 5.2.2 Global CGT Drugs Sales by Region: 2027-2032
- 5.3 Global CGT Drugs Revenue by Region: 2021-2032
- 5.3.1 Global CGT Drugs Revenue by Region: 2021-2026
- 5.3.2 Global CGT Drugs Revenue by Region: 2027-2032
- 5.4 North America CGT Drugs Market Facts & Figures by Country
- 5.4.1 North America CGT Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America CGT Drugs Sales by Country (2021-2032)
- 5.4.3 North America CGT Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe CGT Drugs Market Facts & Figures by Country
- 5.5.1 Europe CGT Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe CGT Drugs Sales by Country (2021-2032)
- 5.5.3 Europe CGT Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific CGT Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific CGT Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific CGT Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific CGT Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America CGT Drugs Market Facts & Figures by Country
- 5.7.1 South America CGT Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America CGT Drugs Sales by Country (2021-2032)
- 5.7.3 South America CGT Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa CGT Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa CGT Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa CGT Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa CGT Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global CGT Drugs Sales by Type (2021-2032)
- 6.1.1 Global CGT Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global CGT Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global CGT Drugs Revenue by Type (2021-2032)
- 6.2.1 Global CGT Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global CGT Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global CGT Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global CGT Drugs Sales by Application (2021-2032)
- 7.1.1 Global CGT Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global CGT Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global CGT Drugs Revenue by Application (2021-2032)
- 7.2.1 Global CGT Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global CGT Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global CGT Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 CGT Drugs Value Chain Analysis
- 8.1.1 CGT Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 CGT Drugs Production Mode & Process
- 8.2 CGT Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 CGT Drugs Distributors
- 8.2.3 CGT Drugs Customers
9 Global CGT Drugs Analyzing Market Dynamics
- 9.1 CGT Drugs Industry Trends
- 9.2 CGT Drugs Industry Drivers
- 9.3 CGT Drugs Industry Opportunities and Challenges
- 9.4 CGT Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst